OR 101
Alternative Names: OR-101Latest Information Update: 18 Apr 2024
At a glance
- Originator Ornovi
- Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies; Small molecules
- Mechanism of Action Emt protein-tyrosine kinase inhibitors; Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alopecia areata; Inflammation; Psoriasis; Vitiligo
Most Recent Events
- 05 Apr 2024 Ornovi withdraws a phase-I trial (In volunteers) in Australia due to reformulation of the drug (PO) (NCT06045624),
- 18 Jul 2023 OR 101 is available for licensing as of 18 Jul 2023. https://ornovi.com/pipeline/
- 03 Jul 2023 Preclinical trials in Alopecia areata in USA (unspecified route) before July 2023 (Ornovi pipeline, July 2023)